U.S. markets open in 8 hours 25 minutes

Nanoform Finland Oyj (NANOFH.HE)

Helsinki - Helsinki Real Time Price. Currency in EUR
Add to watchlist
6.70+0.10 (+1.52%)
At close: 06:29PM EET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.60
Bid6.58 x N/A
Ask6.69 x N/A
Day's Range6.39 - 6.70
52 Week Range4.48 - 8.80
Avg. Volume30,261
Market Cap485.985M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.27
Earnings DateFeb 22, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.27
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for NANOFH.HE

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • PR Newswire

      Nanoform Interim Report January - September 2021

      The strong momentum continues: all near-term business targets for 2021 achieved, rapid customer project intake accelerating, commercial team in Europe expanded, more line capacity added, ISMS certificate received, and a new near-term business target introduced: "Biologics pilot line for GMP in 2022".

    • PR Newswire

      Nanoform Interim Report January - June 2021

      The strong momentum continues: Additional line capacity, more projects, new clients, the number of employees crosses 100, while the gross margin forcefully breaks through 90 per cent. Letter of intent signed for the development, manufacturing, and commercialization of a by nanoforming improved version of a current blockbuster drug.

    • PR Newswire

      Nanoform and Boehringer Ingelheim execute master services agreement

      Nanoform, an innovative nanoparticle medicine enabling company, announces that Proof of Concept studies may now be performed for Boehringer Ingelheim to assess the added value Nanoform's award-winning CESS® technology can deliver to its drug development projects.